GlassScriptPhysician profile
Stephen P Esposito
NPI 1639165293
$190,143.38
in general payments reported to CMS, 2019-2025
45 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $11K · 2021: $35K · 2022: $26K · 2023: $11K · 2024: $11K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $8,913 · Travel and Lodging: $3,890 · Debt Forgiveness: $2,057 · Education: $39.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,465.50 |
| Food and Beverage | $8,912.67 |
| Travel and Lodging | $3,890.04 |
| Debt Forgiveness | $2,056.74 |
| Education | $39.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100,347.92 | 2019-2025 | |
| Gilead Sciences, INC. | $44,115.60 | 2019-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $32,945.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,790.51 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Olympus America INC. | $2,056.74 | 2024 | Single Use Electrosurgical Snare Sd-400, Disposable Biopsy Forceps, Single Use Electrosurgical Hemostatic Forceps |
| Takeda Pharmaceuticals U.S.A., INC. | $1,162.54 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $737.33 | 2019-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $623.63 | 2020-2023 | |
| Pfizer INC. | $486.95 | 2019-2025 | |
| Janssen Biotech, INC. | $453.95 | 2019-2024 | Stelara, Remicade, Simponi |
| Ardelyx, INC. | $396.36 | 2022-2025 | Ibsrela |
| Intra-Sana Laboratories | $380.77 | 2021-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Phathom Pharmaceuticals, INC. | $366.87 | 2023-2025 | Voquezna |
| Redhill Biopharma INC. | $353.07 | 2020-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $339.35 | 2019-2024 | Ocaliva |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $278.04 | 2024-2025 | Iqirvo, Bylvay |
| Cumberland Pharmaceuticals, INC. | $275.35 | 2019-2022 | |
| Celgene Corporation | $266.11 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $220.34 | 2019-2022 | |
| Allergan, INC. | $214.26 | 2019-2020 | |
| Qol Medical, LLC | $170.56 | 2019-2025 | Sucraid |
| Bayer Healthcare Pharmaceuticals INC. | $140.46 | 2019-2020 | |
| Lilly USA, LLC | $103.77 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Braintree Laboratories, INC. | $97.99 | 2019-2024 | Sutab, Suflave |
| Shire North American Group INC | $89.20 | 2019 | |
| Alfasigma USA, INC. | $88.30 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $66.00 | 2023 | Dupixent |
| Evoke Pharma, INC. | $62.20 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $61.49 | 2021-2023 | Gore Cardioform Septal Occluder |
| Shionogi INC | $52.85 | 2019 | |
| Celltrion USA INC. | $52.75 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $48.47 | 2023 | Amjevita |
| Biolase, INC. | $37.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.62 | 2023 | Cyltezo |
| Boston Scientific Corporation | $30.94 | 2023 | Therasphere Administration Set |
| Alnylam Pharmaceuticals INC. | $30.85 | 2022 | |
| Glaxosmithkline, LLC. | $27.02 | 2025 | |
| Novo Nordisk INC | $21.10 | 2025 | Wegovy |
| Capsovision, INC. | $19.91 | 2024 | Capsocam Plus |
| Astrazeneca Pharmaceuticals LP | $18.88 | 2019 | |
| Daiichi Sankyo INC. | $18.29 | 2021 | |
| Merck Sharp & Dohme LLC | $16.75 | 2019 | |
| Exact Sciences Corporation | $16.60 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $14.31 | 2023 | |
| Endo Pharmaceuticals INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.